Univariate analysis of risk factors for PFS and OS for DLBCL patients treated with R-CHOP
| Risk factor . | PFS P . | OS P . |
|---|---|---|
| MYC+ | .006 | .016 |
| IPI ≥ 3 | < .001 | < .001 |
| Non-GCB phenotype | .041 | .058 |
| BCL2 protein* | .313 | .492 |
| Ki-67 | ||
| More than 80% | .582 | .418 |
| More than 90% | .759 | .751 |
| More than 95% | .351 | .642 |
| Extranodal sites, any | .014 | .034 |
| Extranodal sites > 1 | .013 | .040 |
| Bone marrow DLBCL+ | < .001 | < .001 |
| Testicular | .124 | .263 |
| Bulky disease | .334 | .841 |
| Risk factor . | PFS P . | OS P . |
|---|---|---|
| MYC+ | .006 | .016 |
| IPI ≥ 3 | < .001 | < .001 |
| Non-GCB phenotype | .041 | .058 |
| BCL2 protein* | .313 | .492 |
| Ki-67 | ||
| More than 80% | .582 | .418 |
| More than 90% | .759 | .751 |
| More than 95% | .351 | .642 |
| Extranodal sites, any | .014 | .034 |
| Extranodal sites > 1 | .013 | .040 |
| Bone marrow DLBCL+ | < .001 | < .001 |
| Testicular | .124 | .263 |
| Bulky disease | .334 | .841 |
Results using the Dako antibody; not available in 1 MYC− case.